IgA vasculitis (also called Henoch–Schönlein purpura) is a type of small-vessel vasculitis, meaning it causes inflammation in the body’s tiny blood vessels. It often affects the skin, joints, intestines, and kidneys. The condition is more common in children but can also occur in adults. A key feature is the buildup of IgA antibodies in blood vessel walls, which leads to symptoms such as purpura (a raised purple skin rash), joint pain, abdominal pain, and sometimes blood or protein in the urine. Most cases in children resolve on their own, but adults and those with kidney involvement may need treatment. IgA vasculitis is considered part of the CHCC 2012 classification of primary vasculitis.
Vasculitis International is pleased to extend its warmest congratulations to the Vasculitis Foundation (VF) on the occasion of its 40th anniversary. On behalf of the
Vasculitis International has published its position statement on the ongoing regulatory review of TAVNEOS® (avacopan) — and warns that data integrity and risk/benefit analysis are two very different issues and must not be treated as one, when taking action. Otherwise the patient pays for science failure.
The FDA has moved from a review to a formal proposal to withdraw approval of Tavneos in the United States.
This is a more serious step than a review, but it is still not a final decision.
In Europe, the EMA review is still ongoing. No conclusions have been reached yet, and Tavneos is still available.